Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: Implication for tailored treatments of BRCA1 mutation carriers

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 844-854

  Santarosa, Manuela ^a   Del Col, Laura ^a   Tonin, Elena ^a   Caragnano, Angela ^a   Viel, Alessandra ^a   Maestro, Roberta ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BRCA1 PROTEIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CROSS LINKING REAGENT; MITOMYCIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL AGING; CELL DEATH; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TECHNOLOGY; HETEROZYGOTE; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; BREAST TUMOR; CELL CULTURE; CELL LINE; DRUG EFFECT; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PREMATURE AGING;

AGING, PREMATURE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL AGING; CELL LINE, TRANSFORMED; CELLS, CULTURED; CISPLATIN; COLONY-FORMING UNITS ASSAY; CROSS-LINKING REAGENTS; DOXORUBICIN; ETOPOSIDE; HUMANS; MITOMYCIN;

EID: 66449127104     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0951     Document Type: Article

References (42)

1. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-182 (Pubitemid 34161138)
2. Kim H, Chen J. New players in the BRCA1-mediated DNA damage responsive pathway. Mol Cells 2008;25:457-461
3. Bochar DA, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000;102:257-265
4. Silver DP, Dimitrov SD, Feunteun J, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell 2007;128:991-1002. (Pubitemid 46341424)
5. McPherson JP, Hande MP, Poonepalli A, et al. A role for Brca1 in chromosome end maintenance. Hum Mol Genet 2006;15:831-838 (Pubitemid 43338226)
6. French JD, Dunn J, Smart CE, Manning N, Brown MA. Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines. Genes Chromosomes Cancer 2006;45:277-289 (Pubitemid 43238478)
7. Aiyar S, Sun JL, Li R. BRCA1: a locus-specific "liaison" in gene expression and genetic integrity. J Cell Biochem 2005;94:1103-1111
8. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-939 (Pubitemid 30253002)
9. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004;95:866-871 (Pubitemid 40045520)
10. Foray N, Marot D, Gabriel A, et al. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J 2003;22:2860-2871 (Pubitemid 36712381)
11. Yan Y, Black CP, Cao PT, et al. γ-Irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1. Cancer Res 2008;68:5113-5121
12. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921 (Pubitemid 40559006)
13. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008;8:363-369
14. Sgagias MK, Wagner KU, Hamik B, et al. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004;3:1451-1456 (Pubitemid 40310683)
15. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-6228 (Pubitemid 37255167)
16. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-1291 (Pubitemid 36606348)
17. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003;22:1169-1173
18. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007;67:7078-7081 (Pubitemid 47206532)
19. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001;61:4842-4850 (Pubitemid 32691900)
20. Hartley JM, Spanswick VJ, Gander M. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-512 (Pubitemid 29131958)
21. Dronkert MLG, Kanaar R. Repair of DNA interstrand cross-links. Mutat Res 2001;486:217-247 (Pubitemid 32763210)
22. Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999;59:3761-3767 (Pubitemid 29381884)
23. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-346 (Pubitemid 34606876)
24. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485 (Pubitemid 37279334)
25. Egawa C, Motomura K, Miyoshi Y, et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003;78:45-50. (Pubitemid 36223016)
26. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608-610 (Pubitemid 34864568)
27. Goffin JR, Chappius PO, Bégin LR, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003;97:527-536 (Pubitemid 36125829)
28. Järvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847 (Pubitemid 30626942)
29. Geisler S, Lønning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-2512 (Pubitemid 32685830)
30. Baldeyron C, Jacquemin E, Smith J, et al. A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. Oncogene 2002;21:1401-1410 (Pubitemid 34214505)
31. 1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. Int J Radiat Oncol Biol Phys 2004;58:470-478
32. Shanley S, McReynolds K, Ardern-Jones A, et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006;12:7025-7032 (Pubitemid 44974499)
33. Shanley S, McReynolds K, Ardern-Jones A, et al. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 2006;12:7033-7038 (Pubitemid 44974500)
34. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2006;283:2260-2265
35. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13:7413-7420
36. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006;5:135-142 (Pubitemid 43824469)
37. Havelka AM, Berndtsson M, Olofsson MH, Shoshan MC, Linder S. Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an "off-target" effect? Mini Rev Med Chem 2007;7:1035-1039
38. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-237 (Pubitemid 40314954)
39. Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007;120:175-180 (Pubitemid 44901933)
40. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-1883
41. Hotta K, Tabata M, Kiura K, et al. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. Oncol Rep 2007;17:313-317
42. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764 (Pubitemid 46797958)